title: Tau: From research to clinical development.
abstract: Alzheimer's Association Research Roundtable Fall 2015-Tau: From research to clinical development. Tau pathology is recognized as the key driver of disease progression in Alzheimer's and other neurodegenerative diseases. Although this makes tau an attractive target for the development of novel diagnostic and therapeutic strategies, the mechanisms underlying the onset and progression of tau-related neurotoxicity remain elusive. Recent strides in the development of sophisticated preclinical models and the emergence of tau PET imaging and fluid biomarkers provide new opportunities to increase our understanding of tau biology, overcome translational challenges, and accelerate the advancement of tau therapeutics from bench to bedside. With this in mind, the Alzheimer's Association convened a Research Roundtable in October 2015, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of tau pathogenic pathways and review the evolution of tau therapeutics and biomarkers currently in development. The meeting provided a forum to share experience and expertise with the common goal of advancing the discovery and development of new treatment strategies and expediting the design and implementation of efficient clinical trials.
authors.affiliation: Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO, USA. Electronic address: holtzman@neuro.wustl.edu.
authors.forename: David M
authors.initials: DM
authors.lastname: Holtzman
authors.affiliation: Medical & Scientific Relations, Alzheimer's Association, Chicago, IL, USA.
authors.forename: Maria C
authors.initials: MC
authors.lastname: Carrillo
authors.affiliation: Medical & Scientific Relations, Alzheimer's Association, Chicago, IL, USA.
authors.forename: James A
authors.initials: JA
authors.lastname: Hendrix
authors.affiliation: Independent Science Writer, Elverson, PA, USA.
authors.forename: Lisa J
authors.initials: LJ
authors.lastname: Bain
authors.affiliation: Piramal Imaging GmbH, Berlin, Germany.
authors.forename: Ana M
authors.initials: AM
authors.lastname: Catafau
authors.affiliation: AbbVie, North Chicago, IL, USA.
authors.forename: Laura M
authors.initials: LM
authors.lastname: Gault
authors.affiliation: Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom.
authors.forename: Michel
authors.initials: M
authors.lastname: Goedert
authors.affiliation: German Center for Neurodegenerative Diseases (DZNE), CAESAR Research Center, Bonn, Germany.
authors.forename: Eckhard
authors.initials: E
authors.lastname: Mandelkow
authors.affiliation: German Center for Neurodegenerative Diseases (DZNE), CAESAR Research Center, Bonn, Germany.
authors.forename: Eva-Maria
authors.initials: EM
authors.lastname: Mandelkow
authors.affiliation: Bracket Global, Wayne, PA, USA.
authors.forename: David S
authors.initials: DS
authors.lastname: Miller
authors.affiliation: F. Hoffmann-La Roche Ltd, Neuroscience, Basel, Switzerland.
authors.forename: Susanne
authors.initials: S
authors.lastname: Ostrowitzki
authors.affiliation: Novartis Institute of Biomedical Research, Cambridge, MA, USA.
authors.forename: Manuela
authors.initials: M
authors.lastname: Polydoro
authors.affiliation: Merck, West Point, PA, USA.
authors.forename: Sean
authors.initials: S
authors.lastname: Smith
authors.affiliation: Biogen, Cambridge, MA, USA.
authors.forename: Marion
authors.initials: M
authors.lastname: Wittmann
authors.affiliation: Eli Lilly, Inc, Windlesham, Surrey, UK.
authors.forename: Michael
authors.initials: M
authors.lastname: Hutton
mesh_terms: D000544:Alzheimer Disease / Q000473:pathology; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D004195:Disease Models, Animal; D018450:Disease Progression; D006801:Humans; D016874:Neurofibrillary Tangles / Q000473:pathology; D010766:Phosphorylation; D024801:Tauopathies; D016875:tau Proteins / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D016875:tau Proteins
keywords: Alzheimer's disease; Biomarkers; Neurofibrillary tangles; Tau; Tauopathies